- Home
- TULP vs VYNE Comparison
TULP vs VYNE Comparison
Compare TULP & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TULP | VYNE |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | United States |
| Employees | 160 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 22.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TULP | VYNE |
|---|---|---|
| Price | $4.05 | $0.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.6K | ★ 223.3K |
| Earning Date | 02-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.61 | $0.29 |
| 52 Week High | $4.79 | $1.96 |
Technical Indicators
Market Signals| Indicator | TULP | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 59.36 |
| Support Level | $3.65 | $0.56 |
| Resistance Level | $4.06 | $0.69 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 67.80 | 59.56 |
Price Performance
Historical ComparisonAbout TULP Bloomia Holdings Inc. Common Stock
Bloomia Holdings Inc is a specialty ag company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.